Guardant Health, Inc. (NASDAQ:GH - Get Free Report) shares were up 4.5% on Friday . The stock traded as high as $39.93 and last traded at $40.28. Approximately 175,982 shares were traded during trading, a decline of 92% from the average daily volume of 2,124,892 shares. The stock had previously closed at $38.55.
Wall Street Analysts Forecast Growth
Several equities research analysts have recently weighed in on GH shares. Stephens reiterated an "overweight" rating and set a $55.00 target price on shares of Guardant Health in a research note on Wednesday, March 26th. JPMorgan Chase & Co. increased their target price on shares of Guardant Health from $50.00 to $55.00 and gave the stock an "overweight" rating in a research note on Friday, February 21st. Mizuho started coverage on shares of Guardant Health in a research note on Thursday, April 10th. They set an "outperform" rating and a $55.00 target price for the company. Canaccord Genuity Group increased their target price on shares of Guardant Health from $60.00 to $65.00 and gave the stock a "buy" rating in a research note on Thursday, May 1st. Finally, UBS Group increased their target price on shares of Guardant Health from $65.00 to $70.00 and gave the stock a "buy" rating in a research note on Thursday, May 1st. Twenty-one research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $52.32.
View Our Latest Stock Report on GH
Guardant Health Trading Up 5.7%
The company has a 50 day moving average price of $42.68 and a 200 day moving average price of $40.56. The firm has a market cap of $5.05 billion, a PE ratio of -11.45 and a beta of 1.49.
Guardant Health (NASDAQ:GH - Get Free Report) last issued its quarterly earnings data on Wednesday, April 30th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.08. Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. The firm had revenue of $203.47 million during the quarter, compared to the consensus estimate of $189.91 million. During the same period in the previous year, the firm posted ($0.46) EPS. The company's quarterly revenue was up 20.8% compared to the same quarter last year. As a group, equities research analysts anticipate that Guardant Health, Inc. will post -2.9 earnings per share for the current fiscal year.
Insider Buying and Selling
In other Guardant Health news, CEO Amirali Talasaz sold 106,784 shares of Guardant Health stock in a transaction that occurred on Thursday, May 1st. The shares were sold at an average price of $49.01, for a total value of $5,233,483.84. Following the completion of the sale, the chief executive officer now directly owns 2,202,672 shares of the company's stock, valued at approximately $107,952,954.72. The trade was a 4.62% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold 107,132 shares of company stock worth $5,248,393 in the last ninety days. Insiders own 6.10% of the company's stock.
Institutional Trading of Guardant Health
Hedge funds and other institutional investors have recently bought and sold shares of the company. R Squared Ltd purchased a new stake in Guardant Health in the 4th quarter worth approximately $26,000. SBI Securities Co. Ltd. purchased a new stake in Guardant Health in the 4th quarter worth approximately $43,000. SVB Wealth LLC purchased a new stake in Guardant Health in the 1st quarter worth approximately $54,000. Kimelman & Baird LLC purchased a new stake in Guardant Health in the 4th quarter worth approximately $58,000. Finally, NewEdge Advisors LLC grew its stake in Guardant Health by 13.5% in the 4th quarter. NewEdge Advisors LLC now owns 1,929 shares of the company's stock worth $59,000 after acquiring an additional 230 shares during the period. 92.60% of the stock is owned by hedge funds and other institutional investors.
Guardant Health Company Profile
(
Get Free Report)
Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.
See Also
Before you consider Guardant Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Guardant Health wasn't on the list.
While Guardant Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
